Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

He also sardonically targeted co-host David Faber and said “Look I’m sure that when they discovered the cotton gin, and ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

While the TikTok ban has lawmakers scurrying and chatter about Chinese influence over U.S. tech at a fever pitch, another ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 ...

One of Novo Nordisk's (NOVOb.CO), opens new tab next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage ...

2-Year U.S. Treasury Note Continuous Contract $102.746 0.020 0.02% 5-Year U.S. Treasury Note Continuous Contract $106.125 0.055 0.05% 10-Year U.S. Treasury Note Continuous Contract $108.438 0.063 ...